2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

O’Gara, Patrick T.; Kushner, Frederick G.; Ascheim, Deborah D.; Casey, Donald E.; Chung, Mina K.; Lemos, James A. de; Ettinger, Steven M.; Fang, James C.; Fesmire, Francis M.; Franklin, Barry A.; Granger, Christopher B.; Krumholz, Harlan M.; Linderbaum, Jane A.; Morrow, David A.; Newby, L. Kristin; Ornato, Joseph P.; Ou, Narith N.; Radford, Martha J.; Tamis‐Holland, Jacqueline E.; Tommaso, Carl L.; Tracy, Cynthia M.; Woo, Y. Joseph; Zhao, David

doi:10.1002/ccd.24776

Cited by 348 publications

(127 citation statements)

References 203 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…All participants were scanned at the same center and on the same scanner. Diagnosis and treatment of STEMI were as per current guidelines 18, 19. Study exclusion criteria were previous MI and standard recognized contraindications to CMR (eg, ferromagnetic implants, claustrophobia, and estimated glomerular filtration rate <30 mL/min).…”

Section: Methodsmentioning

confidence: 99%

Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Post–Reperfused ST‐Elevation Myocardial Infarction

Bulluck

Rosmini

Abdel‐Gadir

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundWhether the remote myocardium of reperfused ST‐segment elevation myocardial infarction (STEMI) patients plays a part in adverse left ventricular (LV) remodeling remains unclear. We aimed to use automated extracellular volume fraction (ECV) mapping to investigate whether changes in the ECV of the remote (ECVR emote) and infarcted myocardium (ECVI nfarct) impacted LV remodeling.Methods and ResultsForty‐eight of 50 prospectively recruited reperfused STEMI patients completed a cardiovascular magnetic resonance at 4±2 days and 40 had a follow‐up scan at 5±2 months. Twenty healthy volunteers served as controls. Mean segmental values for native T1, T2, and ECV were obtained. Adverse LV remodeling was defined as ≥20% increase in LV end‐diastolic volume. ECVR emote was higher on the acute scan when compared to control (27.9±2.1% vs 26.4±2.1%; P=0.01). Eight patients developed adverse LV remodeling and had higher ECVR emote acutely (29.5±1.4% vs 27.4±2.0%; P=0.01) and remained higher at follow‐up (28.6±1.5% vs 26.6±2.1%; P=0.02) compared to those without. Patients with a higher ECVR emote and a lower myocardial salvage index (MSI) acutely were significantly associated with adverse LV remodeling, independent of T1Remote, T1Core and microvascular obstruction, whereas a higher ECVI nfarct was significantly associated with worse wall motion recovery.Conclusions ECVR emote was increased acutely in reperfused STEMI patients. Those with adverse LV remodeling had higher ECVR emote acutely, and this remained higher at follow‐up than those without adverse LV remodeling. A higher ECVR emote and a lower MSI acutely were significantly associated with adverse LV remodeling whereas segments with higher ECVI nfarct were less likely to recover wall motion.

show abstract

Section: Methodsmentioning

confidence: 99%

Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Post–Reperfused ST‐Elevation Myocardial Infarction

Bulluck

Rosmini

Abdel‐Gadir

et al. 2016

JAHA

View full text Add to dashboard Cite

show abstract

“…For ACS patients receiving DES, the current guidelines recommend prolonged duration of dual antiplatelet therapy (DAPT), although adequate assessment of bleeding risk might be difficult in the setting of emergency PCI. 3 However, the long-term bleeding outcome after DES implantation in real-world ACS patients Unrestricted DES Use in ACS all-cause death and major bleeding. Potential independent variables in the Cox proportional hazard models for all-cause death and major bleeding are shown in Table 1 and Table S1, respectively.…”

Section: Study Populationmentioning

confidence: 99%

“…3 Therefore, another possible concern regarding DES use in ACS patients is the risk of adverse cardiovascular events after early DAPT discontinuation because of bleeding. 22, 23 In the current study, the incidence of major bleeding was relatively low (5.2% at 1 year) despite aggressive use of DES, and no cardiovascular events occurred after DAPT discontinuation in patients with major bleeding.…”

Section: Dapt Duration and Bleeding Outcomes: Landmark Analysis At 1 mentioning

confidence: 99%

Long-Term Efficacy and Safety Outcomes After Unrestricted Use of Drug-Eluting Stents in Patients With Acute Coronary Syndrome

Kawaji

Shiomi

Morimoto

et al. 2014

Circ J

View full text Add to dashboard Cite

1628KAWAJI T et al. Circulation JournalOfficial Journal of the Japanese Circulation Society http://www. j-circ.or.jphas not been thoroughly evaluated yet. To address this issue, the current single center study sought to evaluate the long-term efficacy and safety outcomes, including the incidence of major bleeding, after unrestricted use of DES in the setting of emergency PCI for ACS patients. Methods Study PopulationBetween September 2004 and December 2011, 613 patients were admitted to Kyoto University Hospital with a clinical diagnosis of ACS and underwent emergency PCI. ACS was defined as ST-segment elevation acute myocardial infarction ecent randomized clinical trials comparing secondgeneration drug-eluting stents (DES) with bare-metal stents (BMS) in patients with acute myocardial infarction (MI) have reported comparable safety outcomes, as well as with a significant reduction of target-lesion revascularization (TLR) in DES patients. 1,2 Reflecting these study results, DES use in the setting of acute coronary syndrome (ACS) has become more common in daily clinical practice. For ACS patients receiving DES, the current guidelines recommend prolonged duration of dual antiplatelet therapy (DAPT), although adequate assessment of bleeding risk might be difficult in the setting of emergency PCI. 3 However, the long-term bleeding outcome after DES implantation in real-world ACS patients Background: Recent randomized clinical trials have reported favorable clinical outcomes after the use of drugeluting stents (DES) in patients with acute coronary syndrome (ACS). However, the long-term efficacy and safety outcomes, bleeding outcome in particular, after DES implantation in ACS patients have not been thoroughly evaluated in a real-world population.

show abstract

“…Rapid, potent, and consistent inhibition of platelet aggregation is important in patients with acute STEMI undergoing PCI 4, 5. Compared with the effect of clopidogrel, prasugrel rapidly and more potently inhibits platelet aggregation 6.…”

mentioning

confidence: 99%

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers

Umemura

Iwaki

2016

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

The dosing regimen of prasugrel adjusted for Japanese patients was compared with that of clopidogrel by analyzing the pharmacokinetics and pharmacodynamics in 40 healthy Japanese subjects in a randomized, single‐blind crossover study. In period 1, the subjects received either 300 mg clopidogrel or 20 mg prasugrel; after a >2‐week interval (period 2), the drug was switched. Blood samples of 36 of the 40 subjects were collected for analysis of pharmacokinetics, pharmacodynamics, and CYP2C19 genotypes. The plasma concentration of the active metabolite of prasugrel increased rapidly and reached its peak 30 minutes postadministration, whereas that of the active metabolite of clopidogrel reached its peak 1 hour postadministration. The mean AUC and Cmax of the active metabolite of clopidogrel, but not those of prasugrel, were CYP2C19 genotype dependent. Prasugrel rapidly inhibited platelet aggregation, reaching its maximum effect 1 hour postadministration. Clopidogrel, on the other hand, showed maximum inhibition 2 hours postadministration. Platelet aggregation inhibition by clopidogrel was significantly lower in the poor‐metabolizer subjects than in the extensive‐metabolizer subjects. Overall, prasugrel inhibited platelet aggregation more rapidly and more effectively in healthy Japanese subjects than was observed for clopidogrel.

show abstract

2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Cited by 348 publications

References 203 publications

Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Post–Reperfused ST‐Elevation Myocardial Infarction

Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Post–Reperfused ST‐Elevation Myocardial Infarction

Long-Term Efficacy and Safety Outcomes After Unrestricted Use of Drug-Eluting Stents in Patients With Acute Coronary Syndrome

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers

Contact Info

Product

Resources

About